What changed for Osteoporosis
A plain English summary of what recently moved in the public data Voxsanity tracks for Osteoporosis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 1,676 to 1,665 (-11)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Osteoporosis in July 2026. Voxsanity tracks 10 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 108 trials tracked for Osteoporosis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT02916862 · results posted 29 October 2025
According to the results reported on ClinicalTrials.gov, this trial involved 177 people across four groups. Participants were given one of four combinations: a dietary fibre called Soluble Corn Fiber (SCF) together with calcium, SCF without calcium, a placebo (an inactive substitute) with calcium, or a placebo without calcium. The trial ran for 12 months and was measuring changes in bone mineral content — essentially, the amount of mineral (mainly calcium) stored in bones — across the whole body and in the spine specifically. Bone scans were taken at the start and again after 12 months using a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04079868 · results posted 14 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04079868) looked at a "Bone Health Service" — a structured program to identify and manage low bone density (osteoporosis) in men — compared with usual medical care. A total of 1,888 men were enrolled in the Bone Health Service arm and 1,624 in the usual care arm. The trial measured things like how many men received a bone density scan (called a DXA scan), what their bone density scores looked like, and whether they were prescribed and stayed on bone-related medications. The reported data shows that in the Bone Health Serv...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05338086 · results posted 21 March 2025
According to the results reported on ClinicalTrials.gov, this trial compared a medicine called MB09 — a proposed biosimilar (a near-identical copy of an existing medicine) — against an already-approved medicine called EU-Prolia (denosumab), which is used to treat osteoporosis in postmenopausal women. Osteoporosis is a condition where bones become weaker and more likely to break. The trial enrolled 281 people into the MB09 group and 277 into the EU-Prolia group during its main 12-month phase. A smaller follow-on period ran from months 12 to 18, where participants were reassigned into three grou...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05067335 · results posted 5 December 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 327 participants in total. During the first six months (the "double-blind" phase, where neither participants nor researchers knew who received which treatment), 109 people received a placebo (an inactive injection) and 218 received the study drug, romosozumab. After six months, the trial moved into an open-label phase — where everyone knew what was being given — and all remaining participants received romosozumab for a further six months. The trial was measuring changes in bone mineral density (BMD, a measure of how d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04431960 · results posted 21 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04431960) involved 51 people in total, split across three groups: a "Low-BC" group (17 people), a "High-BC" group (16 people), and a Control group (18 people). Not everyone finished the trial — 16, 11, and 13 people completed it in each group respectively. The trial was measuring changes in bone mineral density (a measure of how dense or strong bones are) and several markers in the blood that are linked to bone health and inflammation. The groups appear to differ by the level of something referred to as "BC," though the da...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05326815 · results posted 24 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 54 participants, all of whom had osteopenia (lower than normal bone density) and had not previously received medical treatment for it. Of those 54 people, 40 completed the study, while 14 did not finish. The trial was measuring how well different methods of testing a bone marker called NTX (a substance found in urine or blood that can reflect how quickly bone is breaking down) agreed with one another. The reported data shows one primary outcome result: a correlation value of 0.52 between the different NTX measurement...
-
NCT02753283 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 201 participants in total — 62 women and 40 men received denosumab (an injectable medicine), while 61 women and 38 men received a placebo (an inactive substitute). All participants had type 2 diabetes and the trial ran for 24 months. The study was measuring changes in bone density — essentially how dense and strong bones are — at several sites in the body, using a type of low-dose X-ray scan. Not everyone finished the trial: around 17–18 women and 11–12 men in each group did not complete it. The reported data shows t...
-
NCT03164928 · results posted 19 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03164928) enrolled 24 participants in total — 16 in the group that received denosumab throughout the study (called "Denosumab/Denosumab") and 8 in the group that started on a placebo (an inactive treatment) before switching to denosumab (called "Placebo/Denosumab"). Almost all participants finished the study — 15 out of 16 in the first group and all 8 in the second group. The trial was measuring changes in bone mineral density (BMD) — a measure of how dense or strong bones are — at the lower spine (lumbar spine) and upper...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04729621 · results posted 18 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04729621) enrolled 166 people in each of two groups during the main treatment period — one group received a medicine called TVB-009 and the other received Prolia (denosumab), a medicine already approved for bone loss. The trial ran in two stages: a main treatment period up to 52 weeks, followed by a transition period up to week 78. The main thing being measured was the change in bone density in the lower spine (lumbar spine) after 52 weeks, assessed using a specialised X-ray scan called a DXA scan. The reported data shows...
-
NCT01144468 · results posted 27 March 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT01144468) involved 351 postmenopausal women, with 176 assigned to take a daily 25 mg dose of exemestane and 175 assigned to take a placebo (a dummy pill with no active ingredient). The trial measured changes in bone density — specifically, the density of bone tissue in a particular part of the body — over a 24-month period. Bone density was measured using a specialised scanning technique called HR-pQCT, which produces detailed images of bone structure. By the end of the study, 124 participants in the exemestane group and 1...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02589600 · results posted 16 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT02589600) enrolled 310 people in total — 154 in the active medication group and 156 in the placebo group (a placebo is a dummy treatment with no active ingredient, used for comparison). The trial was measuring the rate of certain bone fractures — specifically non-traumatic fractures of the spine and other bones identified through imaging such as X-ray, CT, or MRI — expressed as the number of fractures per person per year. Fractures caused by serious accidents, cancer, or involving the toes, fingers, or face were not counte...
-
NCT04026256 · results posted 2 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04026256) enrolled 34 participants in total, divided into three groups: 13 received teriparatide only, 9 received denosumab only, and 12 received a combination of both denosumab and teriparatide. Not everyone finished the study — 10, 8, and 9 participants completed it in each group respectively. The trial was measuring a specific process in bone tissue called the "cancellous bone formation rate," which is essentially a way of quantifying how much new bone was being built inside a particular type of bone tissue (the spongy...
-
NCT02186600 · results posted 27 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 276 women across three groups: a control group (93 people), a risedronate (a bone medication) group (91 people), and an exercise group (92 people). The trial was measuring changes in bone-related outcomes over time, including a measure called the Bone Strength Index (BSI) — a way of estimating how strong the lower leg bone is — as well as bone mineral density (a standard measure of how dense bones are) at the spine, and a blood marker related to how quickly old bone is being broken down by the body. The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04064411 · results posted 15 February 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 511 people in total — 255 in one group and 256 in the other. It compared two different ways of delivering a medicine called abaloparatide: one group received it as a standard injection under the skin (called "Abaloparatide-SC"), while the other received it via a skin patch-like delivery system (called "Abaloparatide-sMTS"). The trial's main goal was to measure changes in bone density in the lower spine after 12 months, with additional measurements taken at the hip and femoral neck (the top of the thigh bone). Around 1...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03812380 · results posted 17 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03812380) enrolled 44 people in total — 22 in a group receiving a supplement called EffCaMgCit (a combination of calcium, magnesium, and citrate) and 22 receiving a placebo (an inactive substitute). The trial was measuring changes over two years in several things related to bone and kidney health, including bone density scores (T-Score and Z-Score), how the body handles magnesium and creatinine (waste products used to assess kidney function), and a hormone called parathyroid hormone (PTH) that helps regulate calcium and bo...
-
NCT03710889 · results posted 15 October 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03710889) enrolled 23 participants, all of whom received at least one dose of the study drug, abaloparatide. Twenty participants completed the study, and three did not. The trial was primarily looking at changes in a bone tissue measurement called mineralising surface/bone surface (MS/BS) — essentially, the proportion of bone surface that is actively forming new bone — taken from a small bone sample (biopsy) at the start of the study and again after three months. Nineteen participants provided bone biopsy samples suitable...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02371252 · results posted 29 September 2021
According to the results reported on ClinicalTrials.gov, this trial involved 140 people in total — 70 in each group. One group took the original brand of alendronate (Fosamax) and the other took a generic version (Bonmax). All 140 participants completed the study, with no drop-outs recorded. The trial was measuring changes in bone mineral density (a measure of how dense or strong bones are) at two locations — the lower spine and the hip — over one year, as well as changes in certain substances in the blood that reflect bone activity. The reported data shows that, after one year, bone mineral...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04271605 · results posted 18 June 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04271605) enrolled 5 participants who received a combined behaviour and medication-based intervention. The trial ran from February 2020 to December 2020, when it was terminated early. Notably, none of the 5 participants completed the study — all 5 are recorded as having not completed it. The trial was measuring four things over that period: deaths, new heart-related events (such as heart attacks or strokes), new fragility fractures (broken bones caused by relatively minor impacts), and fall events. The reported data shows...
-
NCT03051620 · results posted 18 March 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 142 participants in total, with 124 completing the study and 18 not completing it. The trial was looking at what happens to bone density in people who stop taking alendronate (a medication commonly used to strengthen bones), and whether a blood marker called CTX — which reflects how quickly bone is breaking down — could predict who would go on to lose a meaningful amount of bone density in the hip over the following year. The reported data shows that the primary question the trial was trying to answer involved plotti...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00058188 · results posted 19 November 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT00058188) involved two groups of participants: one group received zoledronate along with calcium and cholecalciferol (a form of vitamin D), while the other group received calcium and cholecalciferol alone. The trial was designed to look at changes in bone density over 13 months, as well as other bone-related outcomes such as bone fractures, signs of cancer spreading to the bones, and chemical markers in the blood that reflect how the body is building or breaking down bone. Unfortunately, the participant numbers submitted t...
-
NCT03432533 · results posted 10 April 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 283 people in total — 141 in one group and 142 in the other. Both groups received the same monthly injection of a medicine called romosozumab (210 mg), but through two different delivery devices: a pre-filled syringe (PFS) in one group, and an autoinjector pen (AI/Pen) in the other. The trial was measuring whether the two devices produced similar changes in bone density (a measure of how solid and strong bones are) at the spine and hip over six months. The reported data shows that, for the main measure — change in sp...
-
NCT00745121 · results posted 26 November 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 48 people in total — 20 in the osteoporosis/osteopenia group (people with reduced bone density) and 28 in the control group (people without that condition). The trial was measuring changes in the bone level around dental implants over a five-year period. However, not everyone finished the study: 9 people in the osteoporosis/osteopenia group and 2 in the control group did not complete it, meaning the final results are based on 11 and 26 participants respectively. The reported data shows that the primary outcome being...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01921517 · results posted 15 November 2019
According to the results reported on ClinicalTrials.gov, this trial involved 80 participants in total — 42 in the active treatment group, who received a form of low-level mechanical stimulation (gentle vibration-like stimulation applied to the body), and 38 in the sham group, who received a dummy version of the same device that did not deliver the actual stimulation. The trial was measuring changes in bone quality at the lower leg (the distal tibia), using MRI scans to calculate the ratio of bone tissue to the total volume of the area — a higher ratio suggests denser, healthier-structured bone...
-
NCT02791516 · results posted 5 July 2019
According to the results reported on ClinicalTrials.gov, this trial involved 67 participants in total — 33 receiving a placebo and 34 receiving a medicine called romosozumab (210 mg). The trial ran over six months and was primarily measuring changes in bone mineral density (BMD) — a measure of how dense or strong bones are — at the lower spine (lumbar spine). It also looked at BMD changes at the total hip and the femoral neck (the upper part of the thigh bone where it meets the hip). The reported data shows that, at the lumbar spine, participants in the placebo group had an average change of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01992159 · results posted 25 March 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 252 people in total — 63 in each of four groups. Three groups received different monthly doses of a medicine called romosozumab (70 mg, 140 mg, or 210 mg), while the fourth group received a placebo (a dummy injection with no active medicine). The trial ran for 12 months and was mainly measuring changes in bone mineral density — a way of measuring how dense or strong bones are — at the lower spine (lumbar spine), using a type of scan called a DXA scan. Most participants completed the study, with between 55 and 63 peopl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01588509 · results posted 4 March 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people in total — 30 in each group — who received either a 140 mg or 210 mg dose of a medicine called romosozumab. The main thing the trial was measuring was how much a type of bone density (the amount of mineral in the bones) changed at the lower spine after treatment. Bone density was measured using a type of scan called a DXA scan, which is similar to an X-ray. Almost all participants completed the trial — 29 out of 30 in the lower-dose group and all 30 in the higher-dose group. The reported data shows that, at...
-
NCT01698463 · results posted 18 February 2019
According to the results reported on ClinicalTrials.gov, this trial involved 11 participants, all of whom completed the study with no drop-outs. The trial was looking at whether a program that identified patients at risk and provided them with an exercise prescription could change their physical activity levels over a six-week period. Researchers measured activity in two ways: using a small device worn on the hip (called an accelerometer) that tracked how many minutes per day participants spent moving, and a daily logbook where participants recorded how much of their prescribed exercise they a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01512446 · results posted 17 January 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01512446) involved 436 people in total — 221 who received a placebo (a dummy treatment) and 215 who received a medicine called alendronate, which is used in relation to bone health. The trial was measuring the number of new bone fractures linked to osteoporosis (a condition that weakens bones), as well as deaths and a combined count of fractures or deaths. The reported data shows that when it came to the primary (main) outcome — new osteoporotic fractures — both groups recorded the same number: 5 fractures each. For the s...
-
NCT01631214 · results posted 12 December 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT01631214) involved just over 4,000 postmenopausal women with osteoporosis. Participants were split into two groups of roughly 2,047 each: one group received the medication romosozumab for 12 months followed by alendronate (romosozumab/alendronate), and the other received alendronate throughout the entire period (alendronate/alendronate). The trial measured how often fractures occurred in each group over approximately two years, looking at fractures in the spine as well as elsewhere in the body. The reported data shows the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02016716 · results posted 8 November 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 294 participants across three groups: 53 received a placebo (inactive treatment), 118 received romosozumab at a concentration of 70 mg/mL, and 123 received romosozumab at 90 mg/mL. The trial was measuring changes in bone mineral density (BMD) — a measure of how dense or strong bones are — at several sites in the body, including the lower spine, hip, and femoral neck (the top part of the thigh bone where it meets the hip). It also tracked two chemical markers found in the blood that reflect bone-building and bone-break...
See all 108 reported results for Osteoporosis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research money has been directed toward osteoporosis research in the United States. However, the direction of that funding has been falling year on year, which suggests that institutional enthusiasm for new research investment in this area may be cooling. For patients, this pattern is worth noting, as sustained funding tends to support...
See the full Osteoporosis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.